Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 301–400 of 1,000
Lin, X., Han, X., Kawai, T., & Taubman, M. A. (2010) · Infection and Immunity · doi:10.1128/iai.00944-10 · Cited by 59
Nakamura, Y., Suzuki, T., Kamimura, M., Murakami, K., Ikegami, S., Uchiyama, S., & Kato, H. (2017) · Bone Research · doi:10.1038/boneres.2017.21 · Cited by 56
Iacopo, C., Falchetti, A., Merlotti, D., Cristina, E.-V., & Gennari, L. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1772051 · Cited by 64
Beck, T., Lewiecki, E. M., Miller, P. D., Felsenberg, D., Liu, Y., Ding, B., & Libanati, C. R. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.04.001 · Cited by 55
Self-citationAdvances in bone biology and new treatments for bone loss
Gallagher, J. C. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.04.005 · Cited by 67
Current, new and future treatments of osteoporosis
Salari, P., Abdollahi, M. R., & Larijani, B. A. (2010) · Rheumatology International · doi:10.1007/s00296-010-1586-z · Cited by 59
Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury
Gifre, L., Vidal, J., Carrasco, J. L., Muxí, Á., Portell, E., Monegal, A., Guañabens, N., & Peris, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3333-5 · Cited by 58
Nicotinic acetylcholine receptors modulate osteoclastogenesis
Mandl, P., Hayer, S., Karonitsch, T., Scholze, P., Győri, D., Sykoutri, D., Blüml, S., Mócsai, A., Poór, G., Huck, S., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0961-x · Cited by 58
Advances in treatment of glucocorticoid-induced osteoporosis
Hsu, E., & Nanes, M. S. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000368 · Cited by 56
The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice
Minamizaki, T., Nakao, Y., Irie, Y., Ahmed, F., Itoh, S., Sarmin, N., Yoshioka, H., Nobukiyo, A., Fujimoto, C., Niida, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0754-2 · Cited by 57
RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in Arthropathies
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0298-6_7 · Cited by 59
Kendler, D. L., Bessette, L., Hill, C., Gold, D. T., Horne, R., Varon, S. F., Borenstein, J. E., Wang, H., Man, H., Wagman, R. B., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1023-x · Cited by 63
von Keyserlingk, C., Hopkins, R. B., Anastasilakis, A. D., Toulis, K. A., Goeree, R. A., Tarride, J., & Xie, F. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.03.005 · Cited by 54
Israeli, R., Ryan, C. W., & Jung, L. L. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.09.028 · Cited by 57
Scheiner, S., Pivonka, P., Smith, D. W., Dunstan, C. R., & Hellmich, C. (2014) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2584 · Cited by 52
Mandema, J. W., Zheng, J., Libanati, C. R., & Ruixo, J. J. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3795 · Cited by 53
Yang, S. P., Kim, T. W. B., Boland, P. J., & Farooki, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0192 · Cited by 55
Palmisano, B., Spica, E., Remoli, C., Labella, R., Filippo, A. D., Donsante, S., Bini, F., Raimondo, D., Marinozzi, F., BOYDE, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3828 · Cited by 55
Is Cortical Bone Hip? What determines Cortical Bone Properties?
Epstein, S. (2007) · Bone · doi:10.1016/j.bone.2007.03.006 · Cited by 53
Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria
Heller, H. J., Zerwekh, J. E., Gottschalk, F., & Pak, C. Y. C. (2007) · Kidney International · doi:10.1038/sj.ki.5002181 · Cited by 53
Monoclonal antibodies for treating osteoporosis
Faienza, M. F., Chiarito, M., D’Amato, G., Colaianni, G., Colucci, S. C., Grano, M., & Brunetti, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1401607 · Cited by 55
Ke, D., Ji, L., Wang, Y., Fu, X., Chen, J., Wang, F., Zhao, D., Xue, Y., Lan, X.-H., & Hou, J. (2019) · The FASEB Journal · doi:10.1096/fj.201802597rr · Cited by 56
The Long and the Short of Bone Therapy
Whyte, M. P. (2006) · New England Journal of Medicine · doi:10.1056/nejme068003 · Cited by 52
Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2081 · Cited by 51
Bone Physiology, Disease and Treatment: Towards Disease System Analysis in Osteoporosis
Post, T. M., Cremers, S. C. L. M., Kerbusch, T., & Danhof, M. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318150-000000000-00000 · Cited by 74
Decreased bone mineral density and periodontal management
Reddy, M. S., & Morgan, S. L. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00400.x · Cited by 55
Li, X., Heber, D., Cal-González, J., Karanikas, G., Mayerhoefer, M. E., Rasul, S., Beitzke, D., Zhang, X., Agis, H., Mitterhauser, M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182790 · Cited by 54
Tripto‐Shkolnik, L., Rouach, V., Marcus, Y., Rotman‐Pikielny, P., Benbassat, C. A., & Vered, I. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0389-1 · Cited by 51
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch35 · Cited by 61
Drug Insight: existing and emerging therapies for osteoporosis
Mulder, J. E., Kolatkar, N. S., & LeBoff, M. S. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0325 · Cited by 54
Anti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 56
Self-citationIdris, A. I., Krishnan, M., Šimić, P., Landao‐Bassonga, E., Mollat, P., Vukičević, S., & Ralston, S. H. (2010) · The FASEB Journal · doi:10.1096/fj.10-164095 · Cited by 58
Ho, T., Santora, K. A., Chen, J. C., Frankshun, A., & Bagnell, C. A. (2011) · Bone · doi:10.1016/j.bone.2011.03.684 · Cited by 51
Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond
Smith, M. R. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.004 · Cited by 50
Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis
Albert, S. G., & Reddy, S. (2017) · Endocrine Practice · doi:10.4158/ep161678.ra · Cited by 56
Zou, C., Lin, T., Wang, B., Zhao, Z., Ли, Б., Xie, X., Huang, G., Yin, J., & Shen, J. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.100211 · Cited by 50
Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma
Zangari, M., Yaccoby, S., Cavallo, F., Esseltine, D. L., & Tricot, G. J. K. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.047 · Cited by 52
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 55
Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis
Lewiecki, E. M. (2009) · Journal of Women s Health · doi:10.1089/jwh.2008.1086 · Cited by 50
Self-citationMeta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
Chen, J., Zhou, L., Liu, X., Wen, X., Li, H., & Li, W. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01105-1 · Cited by 50
Cancer Treatment–Related Bone Loss: A Review and Synthesis of the Literature
Khan, M. N., & Khan, A. A. (2008) · Current Oncology · doi:10.3747/co.2008.174 · Cited by 53
Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review
Bridgeman, M. B., & Pathak, R. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.008 · Cited by 48
Lathuilière, A., Mach, N., & Schneider, B. L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510578 · Cited by 53
Kamimura, M., Nakamura, Y., Ikegami, S., Uchiyama, S., Kato, H., & Taguchi, A. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3764-7 · Cited by 48
Kahwati, L. C., Kistler, C. E., Booth, G., Sathe, N. A., Gordon, R. D., Okah, E. D., Wines, R., & Viswanathan, M. (2025) · JAMA · doi:10.1001/jama.2024.21653 · Cited by 58
Clinical and therapeutic aspects of osteoporosis
Compston, J. E. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.04.063 · Cited by 57
Current and future treatment options in osteoporosis
Brewer, L., Williams, D. J., & Moore, A. R. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-0999-2 · Cited by 49
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 50
Nyström, A., Kiritopoulos, D., Ullmark, G., Sørensen, J., Petrén‐Mallmin, M., Milbrink, J., Hailer, N. P., & Mallmin, H. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3883 · Cited by 47
Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
Dempster, D. W., Chines, A. A., Bostrom, M. P., Nieves, J. W., Zhou, H., Chen, L., Pannacciulli, N., Wagman, R. B., & Cosman, F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4006 · Cited by 48
Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets
Shi, W., & Siegal, G. P. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.07.002 · Cited by 50
Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates
Kamel, H. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.06.005 · Cited by 47
Gates, M., Pillay, J., Nuspl, M., Wingert, A., Vandermeer, B., & Hartling, L. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02181-w · Cited by 48
Tadrous, M., Wong, L., Mamdani, M., Juurlink, D. N., Krahn, M. D., Lévesque, L. E., & Cadarette, S. M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2576-2 · Cited by 49
Clinical application of biochemical markers of bone turnover
Seibel, M. J. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400006 · Cited by 63
DEVECİ, M. A., Paydaş, S., Gönlüşen, G., Özkan, C., Biçer, Ö. S., & Tekin, M. (2016) · Acta Orthopaedica et Traumatologica Turcica · doi:10.1016/j.aott.2016.03.004 · Cited by 50
Novel Functions of RANK(L) Signaling in the Immune System
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1050-9_9 · Cited by 53
Bone circuitry and interorgan skeletal crosstalk
Zaidi, M., Kim, S.-M., Mathew, M., Korkmaz, F., Sultana, F., Miyashita, S., Gumerova, A. A., Frolinger, T., Moldavski, O., Barak, O., et al. (2023) · eLife · doi:10.7554/elife.83142 · Cited by 45
Pathophysiology and clinical manifestations of osteoporosis
Becker, C. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80062-1 · Cited by 52
Denosumab for the treatment of osteoporosis: A systematic literature review
Silva-Fernández, L., Rosario, M. P., Martínez-López, J. A., Carmona, L., & Loza, E. (2013) · Reumatología Clínica · doi:10.1016/j.reuma.2012.06.007 · Cited by 51
Regulation of Hedgehog signaling Offers A Novel Perspective for Bone Homeostasis Disorder Treatment
Lv, W.-T., Du, D., Gao, R., Yu, C. W., Jia, Y., Jia, Z., & Wang, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163981 · Cited by 49
The Use of Biological Agents in the Treatment of Rheumatoid Arthritis
Fan, P.-T., & Leong, K. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n2p128 · Cited by 45
Lewiecki, E. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca41c · Cited by 45
Self-citationInfluence of RANKL inhibition on immune system in the treatment of bone diseases
Fouque-Aubert, A., & Chapurlat, R. D. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.05.004 · Cited by 49
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Endocrinology · doi:10.1210/en.2006-1475 · Cited by 49
Riggs, M., Bennetts, M., van der Graaf, P., & Martin, S. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.10 · Cited by 43
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis
Josse, R. G., Khan, A. A., Ngui, D., & Marla Shapiro, C. M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.763779 · Cited by 43
Treatment options for glucocorticoid-induced osteoporosis
Chiodini, I., Merlotti, D., Falchetti, A., & Gennari, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721467 · Cited by 48
Polyclonal and Monoclonal Antibodies in Clinic
Wootla, B., Đenić, A., & Rodriguez, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_5 · Cited by 44
Diagnosis and Management of Osteoporosis
Lash, R. W., Nicholson, J. M., Vélez, L., Harrison, R. V., & McCort, J. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.10.009 · Cited by 51
Bone biology and the pathogenesis of osteoporosis
Russell, R. G. G., Espina, B., & Hulley, P. A. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000229521.95384.7d · Cited by 49
Participation of Older People in Preauthorization Trials of Recently Approved Medicines
Beers, E., Moerkerken, D. C., Leufkens, H. G. M., Egberts, T. C. G., & Jansen, P. A. F. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13067 · Cited by 43
Ominsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 45
Nonsurgical Management of Osteolysis
Talmo, C. T., Shanbhag, A. S., & Rubash, H. E. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000246531.59876.a8 · Cited by 43
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
Vallet, S., Julia-Marie, F., Pecherstorfer, M., & Podar, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040202 · Cited by 43
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00924 · Cited by 43
B cell acute lymphoblastic leukemia cells mediate RANK-RANKL–dependent bone destruction
Rajakumar, S. A., Papp, E., Lee, K. K., Grandal, I., Merico, D., Liu, C. C., Allo, B. A., Zhang, L., Grynpas, M. D., Minden, M. D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba5942 · Cited by 44
Update on the treatment of post-menopausal osteoporosis
Cole, Z. A., Dennison, E. M., & Cooper, C. C. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn017 · Cited by 44
Physiology and pathophysiology of the RANKL/RANK system
Hanada, R., Hanada, T., & Penninger, J. M. (2010) · Biological Chemistry · doi:10.1515/bc.2010.149 · Cited by 46
Ross, F. P., & Christiano, A. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28605 · Cited by 55
Effects of pharmacological inhibition of cathepsin K on fracture repair in mice
Soung, D. Y., Gentile, M. A., Duong, L. T., & Drissi, H. (2013) · Bone · doi:10.1016/j.bone.2013.02.010 · Cited by 42
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 41
Self-citationAro, H. T., Nazari‐Farsani, S., Vuopio, M., Löyttyniemi, E., & Mattila, K. T. (2019) · JBMR Plus · doi:10.1002/jbm4.10217 · Cited by 45
New Treatment Modalities in Osteoporosis
CANALIS, E. M. (2010) · Endocrine Practice · doi:10.4158/ep10048.ra · Cited by 45
Bone Loss and Avascular Necrosis of Bone After Hematopoietic Cell Transplantation
McClune, B. L., Majhail, N. S., & Flowers, M. E. D. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2011.10.007 · Cited by 44
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
Rédiní, F., & Heymann, D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00279 · Cited by 44
New Approaches to the Treatment of Osteoporosis
Silva, B. C. C., & Bilezikian, J. P. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-061709-145401 · Cited by 42
Denosumab for bone diseases: translating bone biology into targeted therapy
Tsourdi, E. A., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0454 · Cited by 45
Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review
Diédhiou, D., Cuny, T., Sarr, A., Diop, S. N., Klein, M., & Weryha, G. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.10.009 · Cited by 41
Hautmann, A. H., Elad, S., Lawitschka, Á., Greinix, H., Bertz, H., Halter, J. P., Faraci, M., Hofbauer, L. C., Lee, S. J., Wolff, D., et al. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01264.x · Cited by 42
Migliore, A., Broccoli, S., Massafra, U., Cassol, M., & Frediani, B. (2013) · PubMed · Cited by 45
Rivera-Valentin, R. K., Zhu, L., & Hughes, D. P. M. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0134-4 · Cited by 41
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz321 · Cited by 40
Jähn, K., Wölfel, E. M., Jobke, B., Riedel, C., Hellmich, M., Werner, M., McDonald, M. M., & Busse, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00250 · Cited by 42
The emerging field of osteoimmunology
Mensah, K. A., Li, J., & Schwarz, E. M. (2009) · Immunologic Research · doi:10.1007/s12026-009-8093-x · Cited by 43
Insights into the genetics of osteoporosis from recent genome-wide association studies
Zheng, H., Spector, T. D., & Richards, J. B. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001980 · Cited by 41
Passeri, E., Benedini, S., Costa, E., & Corbetta, S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/352858 · Cited by 39
An Overview of the Pathophysiology of Vascular Calcification in Chronic Kidney Disease
Stompór, T. P. (2007) · Peritoneal Dialysis International · doi:10.1177/089686080702702s37 · Cited by 40
Review of current literature and implications of RANKL inhibitors for oral health care providers
Epstein, M. S., Ephros, H. D., & Epstein, J. B. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.01.046 · Cited by 42
Calcitonin: A useful old friend.
Srinivasan, A., Wong, F. Y. K., & Karponis, D. (2020) · PubMed Central · Cited by 61
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.